Clinical evaluation of metastases of malignant melanoma imaging with99Tcm-glutathione and99Tcm-anti-melanoma antibody: A comparative study

Basit Öğe Kaydı
dc.contributor.authorDuman Y.
dc.contributor.authorBurak Z.
dc.contributor.authorErcan M.T.
dc.contributor.authorDirlik A.
dc.contributor.authorBilkay B.
dc.contributor.authorAkin Y.
dc.contributor.authorTaner M.
dc.contributor.authorBekdik C.F.
dc.date.accessioned2019-10-27T09:01:17Z
dc.date.available2019-10-27T09:01:17Z
dc.date.issued1995
dc.departmentEge Üniversitesien_US
dc.description.abstractThe aim of this investigation was to test for the scintigraphic detection of metastases of malignant melanoma with a new radiopharmaceutical,99Tcm-glutathione (99Tcm-GSH), in comparison with99Tcm- anti-melanoma antibody (99Tcm-AMAb). Glutathione was labelled with99Tcmby a Sn2+reduction method with an efficiency of > 99% as determined by instant thin layer chromatography (ITLC). Anti-melanoma antibody was obtained as a kit from SORIN (Italy) and labelled with99TcmO4. Forty-three patients with a total of 55 biopsy-proven metastatic melanoma foci, 1 ocular melanoma and 20 benign pathologic foci, also confirmed by ultrasound, computed tomography and magnetic resonance imaging, were included in the study after giving their informed consent. Following the intravenous (i.v.) injection of 500 MBq99Tcm-AMAb, scintigraphic images of the involved areas were obtained 6 h post-injection. Three days later, the same patients were given 500 MBq99Tcm-GSH i.v. and images were obtained 6 and 24 h post-injection. The images were classified as positive (focal abnormal accumulation) or negative. Quantitative evaluation was also applied. Regions of interest were drawn over the involved areas and nearby soft tissues and the target-to- nontarget (T/NT) ratios obtained with99Tcm-AMAb (T/NT: 1.92 ± 0.2) and99Tcm-GSH (T/NT: 1.84 ± 0.2) were compared (0.1 < P < 0.3). The sensitivity (and specificity) of99Tcm-AMAb and99Tcm-GSH in the detection of malignant melanoma metastases were 91% (95%) and 84% (90%), respectively. Compared with99Tcm-AMAb, the advantages of99Tcm-GSH are lower levels of blood radioactivity, lower costs and easy in-house preparation. In conclusion, our results show that99Tcm-GSH is a potentially useful radio-pharmaceutical for the detection of metastases of malignant melanoma. © 1995 Chapman and Hall Ltd.en_US
dc.identifier.doi10.1097/00006231-199511000-00009en_US
dc.identifier.endpage935en_US
dc.identifier.issn0143-3636
dc.identifier.issue11en_US
dc.identifier.pmid8587759en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage927en_US
dc.identifier.urihttps://doi.org/10.1097/00006231-199511000-00009
dc.identifier.urihttps://hdl.handle.net/11454/28211
dc.identifier.volume16en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofNuclear Medicine Communicationsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleClinical evaluation of metastases of malignant melanoma imaging with99Tcm-glutathione and99Tcm-anti-melanoma antibody: A comparative studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu